181 related articles for article (PubMed ID: 27053347)
1. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer.
Noronha V; Prabhash K; Joshi A; Patil VM; Talole S; Nakti D; Sahu A; Shah S; Ghosh-Laskar S; Patil PS; Mehta SA; Jambhekar N; Mahajan A; Purandare N
Oncol Res; 2016; 23(4):183-95. PubMed ID: 27053347
[TBL] [Abstract][Full Text] [Related]
2. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
[TBL] [Abstract][Full Text] [Related]
4. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
[TBL] [Abstract][Full Text] [Related]
6. [Weekly paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy for locally advanced non small cell lung cancer].
Wang J; Pang QS; Wang P; Wang J; Wang W
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):769-72. PubMed ID: 18396691
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer.
Wang H; Ryu J; Gandara D; Bold RJ; Urayama S; Tanaka M; Goldberg Z; Follette D; Narayan S; Lau D
J Thorac Oncol; 2007 Feb; 2(2):153-7. PubMed ID: 17410032
[TBL] [Abstract][Full Text] [Related]
10. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
de Vos-Geelen J; Hoebers FJP; Geurts SME; Hoeben A; de Greef BTA; Voncken FEM; Bogers JHA; Braam PM; Muijs CKT; de Jong MA; Kasperts N; Rozema T; Jeene PM; Blom GJ; van Dieren JM; Hulshof MCCM; van Laarhoven HWM; Grabsch HI; Lemmens VEPP; Tjan-Heijnen VCG; Nieuwenhuijzen GAP
Acta Oncol; 2020 Aug; 59(8):895-903. PubMed ID: 32319845
[No Abstract] [Full Text] [Related]
11. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.
Vlacich G; Diaz R; Thorpe SW; Murphy BA; Kirby W; Sinard RJ; Shakhtour B; Shyr Y; Murphy P; Netterville JL; Yarbrough WG; Cmelak AJ
Oncologist; 2012; 17(5):673-81. PubMed ID: 22550060
[TBL] [Abstract][Full Text] [Related]
12. Outcome of Weekly Carboplatin-Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum-Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review.
Owens R; Cox C; Gomberg S; Pan S; Radhakrishna G; Parikh S; Goody R; Hingorani M; Prince S; Bird T; Dorey N; Macgregor U; Al-Chamali H; Hurt C; Mukherjee S
Clin Oncol (R Coll Radiol); 2020 Feb; 32(2):121-130. PubMed ID: 31662220
[TBL] [Abstract][Full Text] [Related]
13. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer.
Jiang DM; Sim HW; Espin-Garcia O; Chan BA; Natori A; Lim CH; Moignard S; Chen EX; Liu G; Darling G; Swallow CJ; Brar S; Brierley J; Ringash J; Wong R; Kim J; Rogalla P; Hafezi-Bakhtiari S; Knox JJ; Jang RW; Elimova E
Oncology; 2021; 99(1):49-56. PubMed ID: 33053548
[TBL] [Abstract][Full Text] [Related]
17. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
18. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
19. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Gray JR; Thomas M; Sutton VM; Davis JL; Kalman LA; Shaffer DW; Yost K; Rinaldi DA; Hainsworth JD
Cancer J; 2003; 9(4):251-60. PubMed ID: 12967135
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
